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Introduction
Enzyme-linked immunosorbent assay (ELISA) [1-5] is one of the 
most commonly used methods for the detection and quantitation of 
antibodies, antigens, hormones, and a large variety of other molecules, 
including synthetic peptides. Indeed, ELISA is extremely popular 
both in research and in clinical studies also because it is relatively 
inexpensive compared with other more sophisticated technologies. 
The most common procedure can be summarized as it follows: a ligand 
(very often an antigen, antibody or peptide) is coated onto the surface 
of each well in micro plates. The residual, non-coated area of the well is 
then saturated with an inert protein or polymer to prevent non-specific 
binding of the subsequent reagents. Subsequently, the molecule to be 
quantified is dispensed in the plate allowing the binding to the ligand. 
Finally, a specific enzyme-conjugated antibody, followed by a specific 
substrate, originates a colored reaction product that is proportional 
to the amount of the bound molecule under investigation and can be 
quantified by photometry.
In ELISA all the reactions occur in a heterogeneous phase, because 
some reagents are in solution, while other ones are adsorbed and 
immobilized. As a result the diffusion constant of the immobilized 
reagent is zero and the overall reaction speed is very low. For this reason 
the incubation times are normally very long, lasting usually hours. 
Here, we describe a rapid and easy method to considerably 
speed up ELISA protocol, based on the transformation of the step in 
which serum antibodies and secondary conjugated antibodies react 
from heterogeneous to homogeneous phase reaction. All the data 
herein reported to optimize this approach refer to an ELISA aimed at 
detecting total immunoglobulin level in mouse sera against the Outer 
Membrane Vesicles (OMV) of Neisseria meningitidis group B [6-8] 
but it could be potentially applied to any other antigen. This assay was 
developed to analyze samples coming from animal studies for vaccine 
development purposes, thus it can be specifically recommended for 
vaccine immunogenicity studies.
Materials and Methods
Plate preparation
The antigen Outer Membrane Vescicles (OMV) was diluted 
in tris(hydroxymethyl)aminomethane (TRIS) buffer (pH 9.0) to a 
concentration of 5.0 µg/ml (expressed as protein concentration). 100 
µl aliquots of this solution were dispensed into each well of 96-well 
microtiter polystyrene plates (Maxisorp Nunc/Thermo; Roskilde, 
Denmark). After an incubation of 2.5 h at 30°C, plates were washed with 
350 µl/well of washing buffer, [10 mM phosphate buffer and 150 mM 
NaCl (pH 7.4)] (PBS) containing 0.05% (vol/vol) Tween 20. Wells were 
then saturated with 250 µl of a 3% (wt/vol) Polyvinylpyrrolidone-15 
(PVP) in distilled water and incubate for 1 h at room temperature (22-
25°C). Plates are then washed 3 times with washing buffer as described 
above.
Conventional ELISA method
Each plate contained a reference mouse serum, represented by a 
pool of sera from mice immunized with OMV vaccine and a quality 
control serum, represented by another pool of immunized mouse sera. 
To the reference serum was assigned a titer of 5000 U/ml (Units/ml) 
(this titer represents the reciprocal of dilution giving A 405 nm=2.5 in 
this assay). Each serum was diluted in dilution buffer [PBS containing 
0.05% (vol/vol) Tween 20, and 2% (wt/vol) of bovine serum albumin]. 
Reference serum was diluted in duplicate starting from a dilution 
1:3,000 and then following a two-fold dilution along the strips. Quality 
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Abstract
In ELISA, ligand is commonly adsorbed to the plastic surface through non-covalent bonds between the 
hydrophobic regions of the ligand and the plastic surface. Thus, all the reactions occur in a heterogeneous phase, 
with some reactants in solution, and some immobilized. As a result, the diffusion constant of immobilized reagents is 
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phase, aimed at speeding up ELISA procedure especially to easily adapt it to robotic systems. Conventional tests 
usually may take up to 5 hours. Our “rapid ELISA” approach considerably reduces this time to less than 30 minutes 
allowing the method to be more suitable for automation.
The rapid ELISA has been set up to analyze samples coming from animal studies for vaccine development 
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used to detect a wide range of antibodies raised against a wide range of antigens.
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control serum and sera to be tested were diluted in the same way as 
reference serum. Before plate dispensing, all dilutions were prepared 
in test tubes or low binding plates (Masterblock; Greiner Bio-One, 
Germany) or tubes. After sample dispensing, plates were incubated for 
2 h at 37°C. Then they were washed with washing buffer. Afterwards 
100 µl of goat anti-mouse IgG (γ-chain specific) conjugated to alkaline 
phosphatase (Sigma Chemical Co., St. Louis, MO, USA) diluted 
1:10,000 in PBS-BSA buffer were added to each plate well. Plates 
were incubated for 2 h at 30°C and washed as already described. A 
chromogenic substrate solution was prepared at the concentration of 
1 mg/ml dissolving p-Nitrophenyl Phosphate (p-NPP) tablets (Sigma 
Chemical Co., St. Louis, MO, USA) in 1.0M Diethanolamine buffer 
pH 9.8 containing 0.5 mM MgCl2 (Sigma Chemical Co., St. Louis, MO, 
USA). Finally 100 µl of the chromogenic solution were dispensed into 
each well. After 30 min at room temperature the reaction was stopped 
with 100 µl of 4N NaOH, and plates were read at 405 nm.
Rapid ELISA procedure
The same reagents and procedures used in conventional method 
were utilized for plate coating and plate saturation. The plate was 
prepared as for the conventional ELISA with the exception that 
samples, reference and quality control sera were diluted in dilution 
buffer containing 1:1,000 goat anti-mouse IgG (γ-chain specific) 
conjugated to alkaline phosphatase (ALP), allowing homogeneous 
phase reaction. The time needed for this step (“pre-incubation”) is 5 
minutes; longer time of pre-incubation was assessed. 100 µl of diluted 
sample were immediately dispensed into the plates (final dilution 
1:6000). As for conventional method all sera were then diluted along 
the strips following a two-fold dilution step. Plates were incubated for 
20 minutes at room temperature. This incubation time was chosen 
because in preliminary setting-up of the assay increasing time up to 30’ 
decreased linearity of the results, while shorter incubation time resulted 
in too low signal (not shown). After incubation, plates were washed 
as described for the conventional method. The chromogenic substrate 
p-NPP solution was prepared according to the procedure already 
described but at the concentration of 3.0 mg/ml and 100 µl aliquots of 
this solution were dispensed into each well. After 10 minutes at room 
temperature the reaction was stopped with 100 µl of 4 N NaOH and 
plates read at 405 nm.
Data reduction and statistical analysis
Non-parametric test were applied. To compare recoveries obtained 
with different serum dilutions Mann-Whitney test was used (Figure 1). 
To evaluate the correlation between rapid and conventional method 
Spearman test was used (Figure 2). All the sera were tested at different 
dilutions and the corresponding absorbance values at 405 nm were 
interpolated on the regression line obtained from absorbance values 
and titers at different dilutions of the reference serum [8].
Results 
Optimization of pre-incubation time and serum dilution
As shown in Figure 1A increasing pre-incubation time did not 
influence the results, thus the assay was carried out with 5 minutes 
pre-incubation. In order to determine the performances of the assay 
several serum dilutions were investigated. As shown in Figure 1B and 
1D the final dilution of sera which gave the best result, i.e., the one 
closest to 100% recovery, was 1:6,000. As defined in FDA Guidance for 
Industry, Bioanalytical Method Validation Guidelines [9], the recovery 
is the detector response obtained from an amount of the analyte 
(serum) added to and extracted from the biological matrix (negative 
serum), compared with the detector response obtained for the true 
concentration of the pure authentic standard. Recovery pertains to 
the extraction efficiency of an analytical method within the limits of 
variability. The non-extracted standards represent 100% recovery (with 
suggested acceptance range between 85 and 115% [9]). The percentage 
of recovery of the values with known titer samples was utilized as an 
indicator to choose the best serum dilution.
Optimization of the dilution of the Alkaline Phosphatase 
(ALP) conjugated antibody
As already stated, the serum samples to be tested were diluted 1:3,000 
in a buffer containing the Alkaline Phosphatase (ALP) conjugated 
antibody. This step was performed in a test tube, allowing the reaction 
between the ALP-conjugated antibody and the immunoglobulins 
present in the serum occurring very rapidly in a homogeneous phase. 
A series of different dilutions of the ALP-conjugated antibody were 
performed in order to identify the best performances in terms of 
accuracy of the test (recovery %): the dilution 1:1,000 was found to be 
the closest to 100% recovery, and thus was used in the study (Figure 
1C).
Optimization of the dilution of the color developing solution
The concentration of p-Nitrophenyl Phosphate in the substrate 
solution was tested starting from 1.0 mg/ml through 4.0 mg/ml, at 
steps of 1.0 mg/ml. The experimental conditions were: Serum dilution 
1:6,000; anti-mouse antibody ALP conjugated 1:1,000; incubation time 
of the homogeneous phase 10 minutes; incubation time of the immune 
complex 30 minutes at room temperature (RT). We observed that the 
assay linearity clearly improved by increasing p-NPP concentration, 
with an optimum at 3.0 mg/ml (data not shown).
Data from rapid and conventional methods highly correlate
Figure 2A shows the high correlation observed between rapid and 
conventional method to detect antibody against OMV of Neisseria 
meningitidis group B in sera from 18 immunized mice. All titers are 
expressed as arbitrary ELISA units/ml (EU/ml). The titration has been 
performed against a reference serum to which an arbitrary value was 
assigned.
Rapid ELISA outperforms conventional ELISA when short 
incubation times are applied
The conditions used for rapid ELISA protocol (secondary Ab 
concentration, serum dilution, incubation times) were also applied in 
parallel to a conventional ELISA method using reference serum against 
FLU antigen (A/California/07/2009, 20,000 EU/ml) in order to compare 
the results of the two methods and to better define the relevance of the 
change of the first incubation step from heterogeneous (conventional 
ELISA) to homogeneous (rapid ELISA) phase, which in this case 
represented the only difference between the two methods. Results 
in Figure 2C show a very low signal obtained with the conventional 
method compared with the rapid one.
To compare the background signal obtained with the two methods, 
a positive control and a negative control (unrelated serum) were 
tested with rapid and conventional methods at the same dilution. By 
conventional ELISA, positive control gave A405=1.721 ± 0.087 (SD) 
(N=8), negative control gave A405=0.082 ± 0.010 (N=12), with an S/N 
ratio=21.0; by rapid ELISA, the corresponding values were 2.512 ± 
0.170 (N=8), 0.125 ± 0.029 (N=12), and 20.1 respectively, with very 
little difference, in particular for S/N ratio.
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for rapid ELISA comprises three steps after plate preparation. First, the 
specific antibody reacts with secondary antibody in a homogeneous, 
liquid phase. Second, the pre-formed immune complex (specific 
antibodies and secondary antibodies) binds to the specific antigen 
coated to the plate. Third, the chromogenic substrate is added and the 
color-generating reaction occurs. 
The considerable reduction of incubation time of the immune 
complexes (20 minutes) as compared with conventional procedure 
(approximately 2 hours plus 2 hours of secondary antibodies 
incubation) is due to the pre-formed immune complexes. In other 
words, in the conventional procedure, a large amount of serum 
antibodies must be attached to the coated plates to give reasonable 
chances to the secondary labeled antibody “to find” and bind them in a 
heterogeneous system during a reasonable time. 
In the proposed rapid ELISA, the vast majority of specific 
serum antibodies were already bound by secondary antibodies in 
the homogenous phase and at a higher concentration of secondary 
conjugated antibody compared with conventional ELISA. Each 
immune complex then will bind to the plate producing an effective 
signal, because it already carries an ALP molecule which will hydrolyze 
the substrate producing a photometric signal. This method, requiring 
Discussion
The rapid ELISA procedure offers the possibility of speeding up 
ELISA in a perspective of applying this method to a robotic system. 
In particular, serum antibodies to be detected and labelled secondary 
antibodies are allowed to react in a test tube. As each reactant is in 
solution, the equilibrium of the reaction (antibody-antigen binding) 
is reached very quickly. Moreover, the use of pre-formed immune-
complex allows in turn shortening also the subsequent steps, and makes 
unnecessary the washings between the incubation with the primary 
and the secondary antibody, needed in the conventional ELISA.
Although the optimization study has been carried out only for 
OMV of Neisseria meningitidis group B, it is applicable to other antigens 
against which antibody titer has to be determined, as demonstrated 
by preliminary results obtained with FLU antigens (Figure 2C), and 
in principle to any kind of ELISA, in particular for immunogenicity 
studies. However, it must be pointed out that, changing the antigen/
antibody to be assessed, the sensitivity and specificity should be 
carefully evaluated and the method validated case by case.
Conclusion
In summary, as schematized in Figure 2D, the proposed method 
 
3 0 0 0 6 0 0 0 9 0 0 0 1 2 0 0 0
9 0
1 0 0
1 1 0
1 2 0
1 3 0
1 4 0
S E R U M R E C IP R O C A L D IL U T IO N
R
E
C
O
V
E
R
Y
(%
)
0.0571
0.1714
0.0286
B 
3 0 0 0 6 0 0 0 9 0 0 0 1 2 0 0 0
1 .6
1 .8
2 .0
2 .2
2 .4
A
4
0
5
n
m
S E R U M R E C IP R O C A L D IL U T IO N
D 
A 
5 1 0 1 5
0
5 0
1 0 0
1 5 0
T IM E (m in u te s )
R
E
C
O
V
E
R
Y
(%
)
C 
1 :5 0 0 1 :1 0 0 0 1 :2 0 0 0 1 :4 0 0 0 1 :8 0 0 0
6 0
8 0
1 0 0
1 2 0
1 4 0
R
E
C
O
V
E
R
Y
(%
)
A L P C O N J U G A T E D A N T IB O D IE S D IL U T IO N
 
Figure 1: Summary of the optimization of the assay conditions.  (A) No differences in % of recovery were obtained by increasing pre-incubation time of the 
immune-complex; N=4. (B) The percentage of recovery vs. serum reciprocal dilution indicates that the serum dilution 1:6,000 is the one closest to 100%. P values 
are reported on the top. (C) The result closest to 100% recovery is obtained using a dilution of 1:1,000 of the ALP-conjugated antibody.  (D) The sensitivity of the 
assay vs. serum reciprocal dilutions; N=3. The serum dilution of 1:6,000, selected because it resulted in the recovery closest to 100%, gives a good sensitivity.
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only brief contact between the immobilized antigens and the sample, 
eliminates long incubation times. This allows specific affinity capture at 
37°C while minimizing non-specific binding and matrix effects, which 
can compromise the performance of traditional ELISAs. It is also 
important to emphasize that this method is very simple, inexpensive 
and straightforward since no sophisticated reagents are required. The 
considerable shortening of the entire procedure is extremely useful for 
high throughput applications and has been successfully implemented 
to high-throughput ELISA in our laboratories.
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Figure 2: Comparison between conventional and rapid ELISA. (A) In both axes are reported the ELISA units per ml (EU/ml) obtained for a given sample with 
each of the methods. The two methods displays high correlation (R=0.9768); N=18. (B) In the linear range of the assay, the values of EU/ml measured by rapid 
ELISA (Y axis) show good correspondence with the known values (X axis). (C) Comparison of results obtained with 2-fold serial dilutions of an anti-FLU A/
California/07/2009 reference serum diluted starting from 1:15,000 by carrying out both rapid and conventional ELISA using the incubation times of the rapid. (D) 
Schematic representation of the rapid ELISA in comparison with the conventional one. 
